Many children continue to use melatonin for years after being prescribed the medication, according to a recent study.
Swedish researchers found that many children and young adults who are prescribed melatonin are still taking it 3 years later and at larger doses.
Using registry data for an urban area centered around Stockholm, the authors determined that 9980 individuals up to aged 25 years were dispensed melatonin in 2016. Most patients (65%) had a neuropsychiatric diagnosis, and only 20% had a sleep disorder.
Prevalence of dispensed melatonin was 0.2% in preschoolers 5 years and younger, 1.4% in children aged 6 to 12 years, 3.4% in adolescents aged 13 to 17 years, and 1.2% in those aged 18 to 25 years.
Comorbid conditions were common, as was polypharmacy, identified in 4567 individuals (46%), more often females than males. Of those who began taking melatonin in 2016, 50% of male patients and 40% of female patients continued to use it throughout the following 3 years, often at increased doses.
Thoughts from Dr. Farber
I, too, would like to see some long-term studies. But given that sleep difficulties are major problems for children and their families, especially when combined with developmental disabilities such as autism, I continue to use melatonin in high doses if needed for these families. For neurotypical children, however, my go-to remains behavioral interventions.
Reference
Tedroff K, von Euler M, Dahlén E. Melatonin usage in children and young adults, a registry-based cohort study. Eur J Paediatr Neurol. 2022;39(30-34). doi:10.1016/j.ejpn.2022.05.007
At-risk adolescents with depression less likely to endorse suicidal thoughts on questionnaire
May 6th 2024Investigators sought to evaluate characteristics of adolescents with a history of depression who do not endorse risk via the PHQ item 9, which is commonly used to screen for self-harm and suicide risk.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.